Good morning, Over the last six-months, biotech stocks have been moving up and down as the world digests every crumb of news about the progress towards a Covid-19 vaccine. While a vaccine is being approved and distributed, we still have to deal with those who are already sick. In short, it’s important to get the vaccine right, but Operation Warp Speed was never about shortcutting science and limited to only a vaccine. It was geared to speeding up production when a vaccine is available and developing new therapeutics along the way. But that doesn’t mean 2021 will be a year-long version of Groundhog’s Day. If there’s anything that President Trump’s treatment has shown investors, it’s that biotech companies may be further down the road towards producing proven antiviral therapies for the novel coronavirus. Leaving the political issues aside, when experimental therapeutics are used (for now) successfully on a 74-year old, overweight man, that’s something to take a serious look into. While it’s far too early to say whether these drugs truly carry the answer, it does confirm what some have suspected from the beginning of the pandemic. Some are even being fast-tracked through the FDA right now. And as you might expect, dozens of companies are developing therapeutic treatments to mitigate the symptoms of infected patients. In this special presentation, we’re highlighting seven companies that you should be paying close attention to. If therapeutics nudge ahead of a vaccine's wide-use, these stocks are likely to make strong upward moves. View the “7 Stocks That May Provide the Real Solution to the Coronavirus Puzzle”
Matthew Paulson
MarketBeat.com | 
Tidak ada komentar:
Posting Komentar